Trump Hits Branded Drugs With 100% Tariff
The White House imposed up to 100% tariffs on imported brand-name pharmaceuticals, the largest US pharma trade barrier ever.
The White House has imposed the largest pharmaceutical trade barrier in US history, threatening tariffs of up to 100% on brand-name drugs imported into the country.
President Trump signed the executive order on 2 April 2026 alongside adjustments to existing duties on steel, aluminium and copper. The pharmaceutical tariff targets companies that have not reduced prices for the US market, with exemptions for those that comply. Generic drugs are excluded.
The practical effect is stark. A branded drug that costs $100 to import would face an additional $100 in duties at the border. That increase hits before wholesale markups, pharmacy margins and insurance processing, meaning the final cost to patients or insurers could rise by significantly more than the tariff alone suggests.
Europe is the most exposed supplier. The majority of branded pharmaceuticals sold in the United States are manufactured by companies headquartered in the UK, Germany, Ireland and Switzerland. Novo Nordisk, Roche, AstraZeneca, Novartis and GSK all ship significant volumes of finished branded products to the US. Ireland, which serves as a European manufacturing hub for several major drugmakers, faces concentrated risk.
The White House has framed the tariff as a negotiating tool rather than a permanent barrier. The order includes carveouts for companies that have already lowered US prices and allows for further exemptions through bilateral deals. CNBC reported that many companies are initially exempt, though the criteria for continued exemption remain unclear.
Industry reaction was immediate. The Pharmaceutical Research and Manufacturers of America warned the tariffs would raise costs for patients. Hospital and pharmacy groups echoed the concern, noting that import costs feed directly into drug pricing formulae used by insurers and pharmacy benefit managers.
The order takes effect in 30 days, giving manufacturers a narrow window to negotiate. Whether this functions as a genuine trade barrier or a pressure lever for price concessions will depend on how many companies secure exemptions in the weeks ahead.